Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Caribou Biosciences Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 examiners and 4 art units, indicating that each pending matter follows a separate examination path.
DAUNER, JOSEPH G is the busiest examiner, with 1 pending matter. The evenly distributed examiner assignments make centralized docket management and consistent portfolio positions especially useful.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAUNER, JOSEPH G | 1 | 56.8% | +35.6% |
| DUFFY, BRADLEY | 1 | 54.5% | +46.0% |
| KONOPKA, CATHERINE ANNE | 1 | 57.2% | +66.3% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17725324 | CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS | PYLA, EVELYN Y | 15d |
| 18704687 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | DAUNER, JOSEPH G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18390978 | TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS | DUFFY, BRADLEY | 45d overdue |
| 17725324 | CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS | PYLA, EVELYN Y | 15d |
| 18704687 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | DAUNER, JOSEPH G | — |
| 18320355 | COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1643 | 1 |
| 1635 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704687 | EXONUCLEASE-COUPLED REAL-TIME ENDONUCLEASE ACTIVITY ASSAY | DAUNER, JOSEPH G | 1682 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18390978 | TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS | DUFFY, BRADLEY | 1643 | §103DP | Final Rejection | 45d overdue | Pending | Dec 20, 2023 |
| 18320355 | COMPOSITIONS AND METHODS OF NUCLEIC ACID-TARGETING NUCLEIC ACIDS | KONOPKA, CATHERINE ANNE | 1635 | §112Other | Final Rejection | — | Pending | May 19, 2023 |
| 17725324 | CRISPR ABASIC RESTRICTED NUCLEOTIDES AND CRISPR ACCURACY VIA ANALOGS | PYLA, EVELYN Y | 1633 | §102§103 | Non-Final OA | 15d | Pending | Apr 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCaribou Biosciences Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.
Joseph G Dauner has the most, with 1 of Caribou Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.